$7.65 +0.04 (0.52%)

Omeros Corporation (OMER)

Omeros Corporation is an American biopharmaceutical company focused on the discovery, development, and commercialization of drugs for areas such as inflammation, respiratory illness, and Central Nervous System disorders. It leverages its proprietary small-molecule and biologic platforms to develop therapies aimed at underserved medical needs.

🚫 Omeros Corporation does not pay dividends

Company News

Breakout Momentum Plays You Need to Know About
Investing.com • Nathan Reiff • October 23, 2025

The article explores three potential momentum investment opportunities in biotech and battery technology sectors: uniQure, Omeros, and Stardust Power, highlighting their recent developments, financial positions, and analyst expectations.

Complement 3 Glomerulopathy Market Poised for Phenomenal Expansion at a CAGR of 37.2% During the Forecast Period (2025–2034) Owing to the Launch of Promising Therapies Targeting C3, C5, MASP-3, and RNAi | DelveInsight
GlobeNewswire Inc. • Delveinsight • October 22, 2025

The complement 3 glomerulopathy market is projected to grow at a 37.2% CAGR from 2025-2034, driven by increasing disease awareness, advances in complement pathway research, and emerging targeted therapies targeting novel complement mechanisms.

Investor Sentiment Edges Lower, US Stocks Record Gains Last Quarter
Benzinga • Avi Kapoor • April 1, 2024

The CNN Money Fear and Greed index showed a slight decline in overall market sentiment, but it remained in the "Greed" zone on Thursday. U.S. stocks closed mixed on Thursday, while the S&P 500 surged to a new all-time high and also recorded its best first-quarter performance in five years. For the quarter, the S&P 500 gained 10.2% to record its b...

Brian's Big Idea on Biotech
Zacks Investment Research • Brian Bolan • January 10, 2024

A look at drugs for drug addiction and the biotech space.

Why Shares of Omeros Dropped on Monday
The Motley Fool • [email protected] (Jim Halley) • June 12, 2023

The clinical-stage biopharmaceutical released trials data through a presentation.